Latest Announcements

Alivus Life Sciences Ltd has announced its Q2 FY27 results, with revenue growing 16.0% YoY, driven by healthy demand across all key markets and robust contributions from recent launches. The company has also reported a strong free cash flow of ₹2,702 Mn, leading to Cash and Cash Equivalents (including short term investments) of ₹10,116 Mn as of 30th September 2026.

Tamilnad Mercantile Bank Ltd has announced the transcript of its Q2 earnings conference call, where the bank reported a 27.25% year-on-year growth in total business, with net interest income up 4.38% and net profit at a record INR451 crores.

Alivus Life Sciences Limited has released its Q2 FY27 investor presentation, highlighting a 16.0% YoY revenue growth, driven by healthy demand across key markets and robust contributions from recent launches. The company reported a gross margin of 64.4%, up 420 bps QoQ and 670 bps YoY, and an EBITDA margin of 41.8%, up 520 bps QoQ and 880 bps YoY.

Alivus Life Sciences Ltd reported a 16.0% YoY revenue growth in Q2FY27, driven by broad-based momentum in the non-GPL business, with EBITDA margin at a record high of 41.8%. The company generated a strong free cash flow of Rs. 2,702 Mn, leading to Cash and Cash Equivalents (including short-term investments) of Rs. 10,116 Mn as of September 30, 2026.

Alivus Life Sciences Limited has announced its financial results for the second quarter and half-year, ended September 30, 2026, with revenue from operations for Q2FY27 at Rs. 6,820 Mn, a growth of 16.0% YoY, and EBITDA for Q2FY27 stood at Rs. 2,851 Mn, a growth of 47.0% YoY with margins at 41.8%.

Alivus Life Sciences Ltd has announced its unaudited financial results for the second quarter and half year ended September 30, 2026, showing a net profit of ₹1,967.45 crore and ₹3,568.21 crore respectively.

Tamilnad Mercantile Bank Limited has informed the Exchange about the transcript of the earnings conference call hosted by the Bank on the Unaudited Financial Results of the Bank for the quarter and half year ended September 30, 2026, which has been made available on the Bank’s website.

Alivus Life Sciences Ltd has announced its unaudited financial results for the second quarter and half year ended September 30, 2026, showing a net profit of ₹1,967.45 crore and ₹3,568.21 crore respectively.

Sambhv Steel Tubes Limited has informed the Exchange about Investor Presentation for Q2 & H1FY27 financial performance, highlighting revenue growth of 44%, operating EBITDA growth of 68%, and PAT growth of 104% YoY.

Sambhv Steel Tubes Ltd has released an investor presentation for its unaudited financial results for Q2 and H1 FY27, showing revenue, operating EBITDA, and PAT growth of 44%, 68%, and 104% YoY, respectively.

Asset Reconstruction Company (India) Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with a 21% YoY growth in AUM to Rs. 20,274 crore and a 54% YoY increase in PAT to Rs. 290.0 crore.

Shaily Engineering Plastics Ltd has submitted its Investor Presentation for Q2 & H1 FY27, highlighting business updates, key performance highlights, and consolidated financial highlights. The company has received business confirmations, signed new contracts, and launched a new product, Shaily AI Toby Reusable, for GLP-1 therapies. The presentation also includes key consolidated financial highlights, showing revenue growth and improved EBITDA margins.

Strides Pharma Science Ltd reported a strong Q2FY27 with revenue growth of 17% YoY to ₹14,297m, driven by Ex-US Markets. EBITDA grew 8% YoY to ₹2,509m, despite higher raw material, freight and operating costs. Net Debt increased by ₹2,114m during H1 due to an elongated cash-to-cash cycle and higher inventory holding.

Strides Pharma Science Limited has announced its Q2 and H1FY27 earnings, with revenue growing 17% YoY to ₹14,297m and ₹26,951m respectively, driven by Ex-US Markets. EBITDA grew 8% YoY to ₹2,509m and ₹4,807m respectively, despite higher raw material, freight and operating costs. Net Debt increased by ₹2,114m during H1 due to an elongated cash-to-cash cycle and higher inventory holding.

Strides Pharma Science Ltd reported Q2FY27 revenue of ₹14,297m, up 17% YoY, driven by Ex-US Markets growth of 31% YoY. EBITDA grew to ₹2,509m, crossing ₹2,500m for the first time, despite higher input material and freight costs.

Sanofi India Limited has announced its financial results for the quarter ended September 30, 2026, with a 2% growth in domestic net sales and a 4% growth in total net sales compared to the third quarter of 2025. The company has also declared an interim dividend of Rs. 75 per equity share and fixed November 5, 2026, as the record date for the payment of the dividend.

Capital Small Finance Bank Ltd reported unaudited financial results for Q2 FY27, with Gross Advances growing 23.4% Y-o-Y to ₹9,755 crore, Total Deposits rising 16.2% Y-o-Y to ₹10,831 crore, and Profit After Tax increasing 30.7% Y-o-Y to ₹45.61 crore.

Sanofi India Limited has announced its Q3 2026 financial results, reporting a 2% growth in domestic net sales and a 4% growth in total net sales compared to the third quarter of 2025. The company's Insulin portfolio delivered a 9% growth in Q3'26, cementing its leadership in the Diabetes Injectable segment with a 55% market share.

Capital Small Finance Bank Ltd has released its unaudited financial results for the period ended September 30, 2026, showing a 7.5% QoQ and 23.4% YoY growth in loan book, 2.2% QoQ and 16.2% YoY growth in deposits, and a 31% YoY growth in profit after tax.

Capital Small Finance Bank Limited has announced its unaudited financial results for the quarter and half year ended September 30, 2026, with Gross Advances increasing to ₹9,755 crore, total Deposits rising to ₹10,831 crore, and Profit After Tax standing at ₹45.61 crore.